glucose 1-phosphate | 67101-62-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: glucose 1-phosphate
• 英文别名: D-gluco-3,4,5,6-Tetrahydroxy-2-phosphonooxy-hexanal；O²-Phosphono-D-glucose；D-Glucose-2-phosphat；glucose phosphate；glucosephosphate；Phosphoglucose；[(2R,3S,4R,5R)-3,4,5,6-tetrahydroxy-1-oxohexan-2-yl] dihydrogen phosphate
• CAS: 67101-62-6
• 化学式: C₆H₁₃O₉P
• 分子量: 260.138
• InChiKey: GBXZONVFWYCRPT-JGWLITMVSA-N

物化性质

• 沸点：
  681.7±65.0 °C(Predicted)
• 密度：
  1.832±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -4.5
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  165
• 氢给体数：
  6
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  glucose 1-phosphate 在 溴 、 barium carbonate 作用下， 生成 2-phospho-D-gluconic acid
  参考文献：
  名称：

  Courtois; Ramet, Bulletin de la Societe de Chimie Biologique, 1945, vol. 27, p. 614

  摘要：

  DOI：
• 作为产物：
  描述：

  水 、 O³-phosphono-D-glucose; barium salt 生成 glucose 1-phosphate 、 葡萄糖 、 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Brown et al., Chemische Berichte, 1957, vol. 90, p. 936,941

  摘要：

  DOI：

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS ET MÉTHODES POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：CIDARA THERAPEUTICS INC

  公开号：WO2018006063A1

  公开（公告）日：2018-01-04

  Compositions and methods for the treatment of bacterial infections include compounds containing dimers of cyclic heptapeptides conjugated to one or more monosaccharide or oligosaccharide moieties. In particular, compounds can be used in the treatment of bacterial infections caused by Gram-negative bacteria.

  用于治疗细菌感染的组合物和方法包括含有环七肽二聚体与一个或多个单糖或寡糖基团结合的化合物。特别是，这些化合物可用于治疗由革兰氏阴性细菌引起的细菌感染。
• [EN] INDOLE DERIVATIVES INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH)<br/>[FR] INHIBITEURS DE DÉRIVÉS D'INDOLE DE L'ENZYME LACTATE DÉHYDROGÉNASE (LDH)
  申请人：UNIV PISA

  公开号：WO2013092753A1

  公开（公告）日：2013-06-27

  The present invention encompasses compounds having general formula (I) able to inhibit the lactate production (lactic acid) involved in the angiogenesis of tumoral tissues, in the glycolytic metabolic process of tumoral cells, of immune system cells in asthmatic diseases, in vascular cells in the pulmonary hypertension, in the treatment of chronic back pain or hyperoxaluria, and in the process by which the parasites protozoan causing malaria obtain most of the necessary energy

  本发明涵盖了具有一般式（I）的化合物，能够抑制与肿瘤组织血管生成中涉及的乳酸产生（乳酸）有关的过程，抑制肿瘤细胞的糖酵解代谢过程，抑制哮喘疾病中免疫系统细胞的过程，抑制肺动脉高压中血管细胞的过程，用于治疗慢性背痛或高草酸尿症，并抑制引起疟疾的原虫寄生虫获得大部分必要能量的过程。
• COMPOSITIONS COMPRISING AMINO ACID BICARBONATE AND METHODS OF USE THEREOF
  申请人：Kneller Bruce

  公开号：US20090005320A1

  公开（公告）日：2009-01-01

  The invention relates to compositions comprising one or more ionic salts, each of said ionic salts consisting of a bicarbonate anion and a cation selected from the group consisting of an amino acid, an amino acid derivative, a di-peptide and a tri-peptide, and to methods of making and using said compositions.

  该发明涉及包含一种或多种离子盐的组合物，每种离子盐由碳酸氢根阴离子和从氨基酸、氨基酸衍生物、二肽和三肽组成的阳离子中选择的阳离子组成，并涉及制备和使用该组合物的方法。
• [EN] DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-1H-INDOL-3-YL]-METHANONES<br/>[FR] [4-(5-AMINOMÉTHYL-PHÉNYL)-PIPÉRIDIN-1-YL]-1H-INDOL-3-YL]-MÉTHANONES DISUBSTITUÉES
  申请人：SANOFI AVENTIS

  公开号：WO2011022449A1

  公开（公告）日：2011-02-24

  The present invention extends to the compound of formula I: or a prodrug, pharmaceutically acceptable salt, or solvate of said compound. Furthermore, the present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula I, and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed to the use of a compound of formula I as an inhibitor of tryptase, comprising introducing the compound into a composition comprising tryptase. In addition, the present invention is directed to the use of a compound of formula I for treating a patient suffering from, or subject to, a physiological condition in need of amelioration of an inhibitor of tryptase comprising administering to the patient a therapeutically effective amount of the compound of Claim 1. The present invention is directed also to the preparation of a compound of formula I.

  本发明涉及到式I的化合物：或者该化合物的前药、药用可接受的盐或溶剂。此外，本发明涉及一种包括式I化合物的药物组合物，以及药用可接受的载体的药学有效量。此外，本发明涉及将式I化合物用作色氨酸蛋白酶抑制剂的用途，包括将该化合物引入含有色氨酸蛋白酶的组合物中。此外，本发明还涉及将式I化合物用于治疗患有或患有需要改善色氨酸蛋白酶抑制剂的生理状况的患者的用途，包括向患者施用权利要求1中的化合物的治疗有效量。本发明还涉及制备式I化合物。
• Preparation of pharmaceutical salts of piperazine compounds
  申请人：Wu Wenxue

  公开号：US20060241295A1

  公开（公告）日：2006-10-26

  The present invention is generally directed to a process to directly prepare pharmaceutically acceptable salts enriched with respect to selected rotameric salts of a basic compound, by creative choice of an acid and a solvent medium. The process is particularly useful in preparing specific rotamers of pharmaceutically useful salts in desired preponderance of a rotamer.

  本发明通常涉及一种直接制备药用可接受盐的过程，该过程通过创造性地选择酸和溶剂介质，使其富集于一种基本化合物的选择性转构盐。该过程特别适用于在所需的转构体的优势下制备具有药用价值的盐的特定转构体。